Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group

This publication has 13 references indexed in Scilit:

• Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
  Cancer Investigation, 2004
• Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB
  British Journal of Cancer, 2003
• Increased Muscle Proteasome Activity Correlates With Disease Severity in Gastric Cancer Patients
  Annals of Surgery, 2003
• Modulation of the ubiquitin‐proteasome proteolytic pathway by eicosapentaenoic acid supplementation in a model of progressive malignancy
  Journal of Parenteral and Enteral Nutrition, 2003
• ANTICYTOKINE TREATMENT PREVENTS THE INCREASE IN THE ACTIVITY OF ATP-UBIQUITIN- AND CA2+-DEPENDENT PROTEOLYTIC SYSTEMS IN THE MUSCLE OF TUMOUR-BEARING RATS
  Cytokine, 2002
• Pooling of Prognostic Studies in Cancer of the Pancreatic Head and Periampullary Region: the Triple-P Study
  The European Journal of Surgery, 2000
• Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
  2000
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument
  Quality of Life Research, 1999
• Prognostic effect of weight loss prior tochemotherapy in cancer patients
  The American Journal of Medicine, 1980